A Randomised in Practice Evaluation of the Influence of Patient's Understanding of Her Disease and Therapy on Persistence and Compliance to Adjuvant Therapy for Post-menopausal Hormone Sensitive Early Breast Cancer
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
A Randomised in Practice Evaluation of the Influence of Patient's Understanding of Her Disease and Therapy on Persistence and Compliance to Adjuvant Therapy for Post-menopausal Hormone Sensitive Early Breast Cancer
Inclusion Criteria:
- Histological/cytological confirmed primary diagnosis of early breast cancer
- Postmenopausal
- Hormone receptor positive
Exclusion Criteria:
- Patients with severe renal function disorders
- Patients with moderate or severe disorders of hepatic function
- Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Compliance rate and persistence rate
Outcome Time Frame:
until discontinuation of treatment
Safety Issue:
No
Principal Investigator
AstraZeneca Germany Medical Director
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
1033GR/0002
NCT ID:
NCT00555867
Start Date:
October 2006
Completion Date:
February 2011
Related Keywords:
- Breast Cancer
- hormone-receptor positive primary breast cancer
- compliance
- Postmenopausal women
- Breast Neoplasms
Name | Location |
|---|
